Canada· CA-DIN-02552973
OJJAARA
A momelotinib product containing momelotinib (momelotinib dihydrochloride), registered in Canada by GLAXOSMITHKLINE INC. The same ATC class is registered in 15 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Momelotinib is registered in 15 of 19 countries.
Countries holding a registration under ATC L01EJ04 (momelotinib), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 9 of them publish a price we can compare per daily dose
Momelotinib · ATC L01EJ04
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of momelotinib costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.16 in France to $309.44 in Switzerland — a ×1929 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Momelotinib · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- CH Switzerland$309.44
- FR France$0.16
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- MOMELOTINIB (MOMELOTINIB DIHYDROCHLORIDE)
- Manufacturer
- GLAXOSMITHKLINE INC
- Country
- Canada (CA)
- ATC code
- L01EJ04
- ATC class
- Momelotinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Momelotinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesOjjaaraGlaxoSmithKline LLC
- United KingdomOmjjara 150mg tabletsGlaxoSmithKline UK Ltd
- SwitzerlandOmjjara 100 mg, FilmtablettenGlaxoSmithKline AG
- CzechiaOMJJARAGlaxoSmithKline Trading Services Limited, Dublin
- SpainOMJJARA 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAGlaxosmithkline Trading Services Limited
- FinlandOmjjaraGlaxosmithkline Trading Services Limited
- FranceOMJJARA 100 mg, comprimé pelliculéGLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- BelgiumOmjjara 100 mgGlaxoSmithKline Trading Services
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Omjjara
- Liechtenstein · Omjjara
- Norway · Omjjara
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/06415e9c-efb6-41ac-8686-bc8687409fb5 GET /v1/drugs/06415e9c-efb6-41ac-8686-bc8687409fb5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02552973",
"form": "TABLET",
"class": "Human",
"routes": [
"ORAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "L01EJ04",
"schedule": [
"Prescription"
],
"drug_code": "104194",
"strengths": [
"150 MG"
],
"ahfs_class": null,
"substances": [
"MOMELOTINIB (MOMELOTINIB DIHYDROCHLORIDE)"
],
"product_categorization": null
}See everything about momelotinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.